We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Assay Measuring Eight Cytokine Markers Discriminates Active from Latent Form of Tuberculosis

By LabMedica International staff writers
Posted on 18 Jan 2015
Print article
Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
Image: Mycobacterium tuberculosis (stained purple) in a tissue specimen (blue) (Photo courtesy of the CDC - US Centers for Disease Control and Prevention).
A new real-time reverse transcription-PCR (real-time RT-PCR) assay allows diagnosticians to distinguish between active pulmonary tuberculosis (TB) and the latent form of the disease (LTBI), which are disease states that cannot be differentiated by either the tuberculin skin test (TST) or interferon-gamma release assays (IGRAs).

Investigators at Yonsei University (Republic of Korea) developed a real-time RT-PCR TaqMan assay for targeting levels of eight human targets [IFN-gamma, tumor necrosis factor (TNF)-alpha, IL-2R, IL-4, IL-10, CXCL9, CXCL10, and CXCL11].

TaqMan assays are based on probes that consist of a fluorophore covalently attached to the 5'-end of the oligonucleotide probe and a quencher at the 3'-end. The quencher molecule quenches the fluorescence emitted by the fluorophore when excited by the cycler’s light source via FRET (Fluorescence Resonance Energy Transfer). As long as the fluorophore and the quencher are in proximity, quenching inhibits any fluorescence signals. TaqMan probes are designed such that they anneal within a DNA region amplified by a specific set of primers. As the Taq polymerase extends the primer and synthesizes the nascent strand, the 5' to 3' exonuclease activity of the Taq polymerase degrades the probe that has annealed to the template. Degradation of the probe releases the fluorophore from it and breaks the close proximity to the quencher, thus relieving the quenching effect and allowing fluorescence of the fluorophore. Hence, fluorescence detected in the quantitative PCR thermal cycler is directly proportional to the fluorophore released and the amount of DNA template present in the PCR.

Results obtained with the tuberculosis TaqMan assay showed that the sensitivity of TNF-alpha, IL-2R, and CXCL10 in the active pulmonary tuberculosis (PTB) group was 96.43%, 96.43%, and 100%, respectively. The sensitivity of IL-2R and CXCL10 in the latent tuberculosis infection group was 86.36% and 81.82%, respectively. Statistical results showed that TNF-alpha and CXCL9 were the best individual markers for differentiating between the PTB, LTBI, and non-TB groups.

For optimal sensitivity and differentiation of M. tuberculosis infection status, the investigators attempted simultaneous detection of multiple targets. The combination of IFN-gamma, TNF-alpha, and IL-2R, and the combination of TNF-alpha, IL-2R, CXCL9, and CXCL10 showed the best performance for detecting active PTB (both 100% positivity) and LTBI (86.36% and 81.82% positivity, respectively).

"These results imply that a combination of suitable single markers is very useful for the efficient diagnosis and differentiation of Mycobacterium tuberculosis (MTB) infection," said senior author Dr. Hyeyoung Lee, professor of biomedical laboratory science at Yonsei University. "The World Health Organization reports that one-third of the world's population is latently infected with MTB. It has been estimated that in 5% to 10% of LTBI individuals, the infection progresses to an active disease state, and the conversion rate is greater in immunosuppressed individuals such as those with HIV. Therefore, rapid diagnostic tests and effective treatment of LTBI are important to reduce and control the TB burden."

Details of the study were published in the January 2015 issue of the Journal of Molecular Diagnostics.

Related Links:

Yonsei University


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Centromere B Assay
Centromere B Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.